NICE Treatment Evaluation of Avanafil
NICE has evaluated the erectile dysfunction drug avanafil. Erectile dysfunction is very common, effecting 52% of men aged 40 to 70 years, and has a wide range of causes, which may be related to physical (particularly cardiovascular illness) or psychological problems.
The majority of adverse events are mild moderate, resulting in infrequent discontinuations.
Sildenafil would remain the first choice treatment, as there is no evidence of avanfil superiority and sildenafil it is now available generically at low cost.
Photo taken from here. No changes made.